Geoffrey Gewurz, an Investor, shared Razelle Kurzrock’s, Founding Director at Michels Rare Cancers Research Laboratories, post on X, adding:
“Agree. The real conclusion is not that ctDNA is hype, but that ctDNA is contextual. It should not replace pathology, tissue, or imaging – but it can reveal actionable biology missed by a single tissue biopsy, especially when disease is heterogeneous or tissue is limited. The future is complementary multi-modal testing: tissue + liquid + clinical context + longitudinal outcomes. That is where the real decision layer gets built.”
Quoting Razelle Kurzrock’s post:
“ctDNA often finds actionable alterations not in tissue. Tissue reflects 1 site; CtDNA finds shed DNA from many sites. Complementary. ASCO is conservative. 2017, FDA approved NGS; but ASCO NGS guidelines only in 2022; Because ASCO is cautious, doesn’t mean that ctDNA is hype.”
Rishabh Jain: What ASCO’s ctDNA Guideline Means for Practice
Other articles featuring Razelle Kurzrock on OncoDaily.